분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2016-06-30 08:16:58 , Hit : 966
 Gilead wins U.S. nod for drug for all types of hepatitis C


Life  |  Tue Jun 28, 2016 2:42pm EDT
Related:  Health  


U.S. health regulators on Tuesday approved a combination drug by Gilead Sciences Inc that is the first available treatment for all six major forms of hepatitis C, advancing the company's leadership in the field and sending its shares up more than 4 percent.

Gilead said in a separate statement that it priced the drug at $74,760 for a 12-week regimen.

Gilead has dominated the hepatitis C market over rivals AbbVie and Merck & Co with its high-priced and highly effective treatments Sovaldi and the combination drug Harvoni. The new treatment, to be sold under the brand name Epclusa, combines Sovaldi (sofosbuvir), which was approved in 2013, with a new anti-viral drug velpatasvir.

Epclusa costs less than the $84,000 that Sovaldi sold for when it launched in late 2013. Gilead now offers discounts and rebates on that older drug, which was at the center of a national uproar over soaring drug costs.

Epclusa is approved for patients with and without cirrhosis, a form of scarring seen in patients with advanced disease that can lead to liver failure and need for a transplant. For those with moderate to severe cirrhosis, Epclusa must be taken with the older drug ribavirin, the Food and Drug Administration said.

"This approval offers a management and treatment option for a wider scope of patients with chronic hepatitis C," Edward Cox, director of the FDA's Office of Antimicrobial Products, said in a statement.

While the majority of U.S. patients have the genotype 1 form of hepatitis C, about 20 percent to 25 percent have genotypes 2 or 3, with small numbers infected with genotypes 4, 5 or 6. In other parts of the world, other genotypes are far more prevalent, such as in Egypt, where genotype 4 is widespread.

In pivotal clinical trials, Epclusa led to cure rates of 95 percent to 99 percent in patients without or with mild cirrhosis after 12 weeks of treatment. In a separate trial of patients with moderate to severe cirrhosis, cure rates of 94 percent were seen.

In afternoon trading, Gilead shares were up $3.35, or 4.28 percent at $81.60 on Nasdaq.


(Reporting by Bill Berkrot in New York and Shailesh Kuber in Bengaluru; Editing by Bill Trott and Diane Craft)







1147   DNA Can Be Edited Without Being Cut  이성욱 2016/08/30 1416
1146   Using RNA to Amplify RNA  이성욱 2016/08/16 1030
1145   CRISPR: No Cutting Required  이성욱 2016/08/06 1634
1144   “Kissing Disease” Virus Promotes Malignant Breast Cancer Development  이성욱 2016/08/03 1036
1143   Lytic and latent viral replication prevented with CRISPR/Cas9  이성욱 2016/07/27 916
1142   Chinese Scientists To Test Gene Modifying Technique ‘CRISPR’ On Humans For The First Time  이성욱 2016/07/27 1090
1141   FDA OKs AbbVie's once-daily Viekira XR for HCV-1  이성욱 2016/07/27 903
1140   [미국] 유전자가위 규제 마련 지연과 기업들의 움직임  이성욱 2016/07/21 1100
1139   5년새 20배 성장 `유전자치료제` 시장..경쟁력 확보 필수  이성욱 2016/07/21 985
1138   Revisiting CAR T-Cells for Treating HIV Shows Promise  이성욱 2016/07/19 790
1137   코오롱, 유전자치료제 판매 허가 신청  이성욱 2016/07/12 893
  Gilead wins U.S. nod for drug for all types of hepatitis C  이성욱 2016/06/30 966
1135   줄기세포·유전자치료제 차세대 주자로 급부상  이성욱 2016/06/21 1123
1134   Virus Hacks Host Genome, Steals CRISPR to Protect Itself  이성욱 2016/06/16 834
1133   CRISPR Antidotes Galore  이성욱 2016/06/14 1028
1132   Let’s Synthesize the Human Genome, Says HGP-Write  이성욱 2016/06/04 849
1131   A New CRISPR System for RNA  이성욱 2016/06/04 933
1130   Scientists identify a novel CRISPR system that zeroes in on single-stranded RNA.  이성욱 2016/06/04 834
1129   GSK gets EU approval for first gene therapy for children  이성욱 2016/05/30 871
1128   Gene therapy drug approval granted to GSK  이성욱 2016/05/30 931

[1][2][3][4][5][6] 7 [8][9][10]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN